{"id":967,"date":"2026-04-29T15:24:13","date_gmt":"2026-04-29T15:24:13","guid":{"rendered":"https:\/\/edmpackz.com\/?p=967"},"modified":"2026-04-29T15:24:13","modified_gmt":"2026-04-29T15:24:13","slug":"circumferential-volumetric-modulated-arc-radiotherapy-of-the-lower-legs-a-technique-described-in-a-case-of-disseminated-superficial-actinic-porokeratosis","status":"publish","type":"post","link":"https:\/\/edmpackz.com\/?p=967","title":{"rendered":"Circumferential volumetric modulated arc radiotherapy of the lower legs\u2013a technique described in a case of disseminated superficial actinic porokeratosis"},"content":{"rendered":"
\n

<\/h1>\n

Gerald B. Fogarty,1<\/sup>\u00a0<\/i>\u00a0<\/sup>Chris Farrow,1<\/sup>\u00a0Julie Bartley,1<\/sup>\u00a0Steven Wardle,2<\/sup>\u00a0Reza Rahbari,3<\/sup>\u00a0Chelsie O\u2019 Connor1<\/sup><\/h4>\n

1<\/sup>GenesisCare Radiation Oncology, Mater Hospital, Crows Nest, Australia
\n2<\/sup>Sun Doctors, 200 Crown Street, Wollongong, Australia
\n3<\/sup>GenesisCare Centre for Radiation Oncology, Waratah Private Hospital, Hurstville, Australia<\/p>\n

Correspondence:<\/strong>\u00a0Prof Gerald Fogarty, GenesisCare Radiation Oncology, Mater Hospital, 25 Rocklands Rd, Crows Nest, NSW, 2065, Australia, Tel +612 9458 8050, Fax +612 9929 2687<\/p>\n

Received:<\/span>\u00a0November 05, 2021 |\u00a0Published:<\/span>\u00a0November 25, 2021<\/p>\n

Citation:\u00a0<\/strong>Fogarty GB, Farrow C, Bartley J, et al. Circumferential volumetric modulated arc radiotherapy of the lower legs\u2013a technique described in a case of disseminated superficial actinic porokeratosis.\u00a0Int J Radiol Radiat Ther<\/i>. 2021;8(4):183-192. DOI:\u00a010.15406\/ijrrt.2021.08.00313<\/a><\/p>\n

<\/i>\u00a0Download PDF<\/a><\/p>\n<\/div>\n

Abstract<\/h1>\n
\n

A case of a fit 65-year-old male with a long history of recalcitrant Disseminated Superficial Actinic Porokeratosis (DSAP) treated with Volumetric Modulated Arc Radiotherapy (VMAT) is presented. The whole circumference of both lower legs from knees to ankles were simultaneously treated to 43.2 Gray (Gy) in 24 fractions, one fraction short of the prescription dose of 45 Gy in 25 fractions. There was in-field clearance of DSAP at ten weeks. This is the first publication of circumferential VMAT treatment of the skin of the lower legs. More follow up is required to see the durability of control of DSAP, and more research is needed to test the generalisability of this technique.<\/p>\n

Keywords:<\/strong>\u00a0Radiotherapy, circumferential treatment, lower legs, volumetric modulated arc therapy, disseminated superficial actinic porokeratosis<\/p>\n<\/div>\n

Introduction<\/h1>\n
\n

Disseminated Superficial Actinic Porokeratosis (DSAP) is characterised by small, dry, scaly brown patches with a distinctive border over the skin of the body, particularly in sun exposed areas like the lower arms and legs.1<\/a>,2<\/a><\/sup>\u00a0DSAP usually starts during the third or fourth decade and may be inherited in an autosomal dominant manner or may occur in people with no family history.3<\/a><\/sup>\u00a0Cutaneous squamous cell carcinoma (cSCC) or Bowen\u2019s disease may develop within patches, and so it may be considered as a precursor form of extensive skin field cancerisation (ESFC).4<\/a><\/sup>\u00a0There is no standard treatment for DSAP, and current treatment is generally not effective in the long-term.1<\/a>,2<\/a><\/sup><\/p>\n

Volumetric Modulated Radiotherapy (VMAT) is ideal for treating large convex areas of ESFC.5<\/a><\/sup>\u00a0Treating the lower legs has been a relative contraindication for treating lesions with definitive radiotherapy (RT)6<\/a><\/sup>\u00a0let alone ESFC of the lower legs. Lower leg VMAT for ESFC has been problematic. Our national protocol7<\/a><\/sup>\u00a0for lower legs requires a mandated break of at least two weeks after 18-20 Gy, treating one leg only at a time, and sparing a strip of skin to avoid chronic lymphoedema. The latter is difficult when the full circumference of the lower leg is involved, as it is in DSAP.<\/p>\n

We present a case of DSAP of bilateral lower legs treated simultaneously to one fraction short of the full prescription dose. The full circumference of both legs were treated simultaneously with a good outcome at 10 weeks.<\/p>\n<\/div>\n

Case Study<\/h1>\n
\n

A fit motivated 65-year-old male had suffered from DSAP for 30 years. He had treatment for various small keratinocytic cancers (KCs) treated in sun exposed areas, and field treatments such as 5 fluorouracil cream for symptomatic eruptions of DSAP, without lasting effect. His current strategy at the time of presentation was a review every 3 months by his local skin doctor. The doctor would just cauterise every lesion that looked as though it would transform into a KC, treating about 50 lesions a year.<\/p>\n

The most effective treatment to date was photodynamic therapy (PDT) to both legs. This was painful during administration, with pain lasting for several weeks afterwards. The pain was described as \u201clava\u201d under the skin especially when going from lying to standing. The pain was not pulsating. The PDT had a good effect lasting for 2 to 3 years but then the DSAP reappeared within the PDT treated volumes.<\/p>\n

He has never had any DSAP on the face or torso. His mother had suffered from DSAP. He has one sibling, and that sibling had no sign of DSAP. He had had a left tibial osteotomy in the past but had no history of vascular problems, especially no lower leg varicosities. His main areas of concern with DSAP were bilateral lower legs. He did remark that people had noted his disease and at times he covered his legs for this reason. He lived over 100 kms from the treatment centre and wanted both legs treated at the same time for convenience.<\/p>\n

Examination revealed circumferential involvement of both lower legs, worse anteriorly, consistent with sun exposure. The field change extended onto the proximal dorsum of both feet. There were no active KCs in the leg fields. (Figure 1<\/a>) The rationale, process, and side effects of VMAT for ESFC of both legs was explained and he consented to treatment and proceed to planning. Prior to planning he was reviewed by a lymphoedema physiotherapist and was prescribed compression therapy consisting of below knee flat knit compression stockings and compression wrap garments. The plan was for him to wear these from the beginning of therapy except at night. The garments cost $AUD 500 per leg.<\/p>\n

<\/a><\/p>\n
\n

Figure 1A<\/strong>\u00a0A \u2013 Lower legs at presentation \u2013 anterior view.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 1B<\/strong>\u00a0B \u2013 Lower legs at presentation \u2013 posterior view.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 1C<\/strong>\u00a0C \u2013 Lower legs at presentation \u2013 close up of anterior left leg showing typical skin lesions of DSAP. Black arrows indicate small, dry, scaly brown patches with a distinctive border all over the skin.
\nFigure 1<\/strong>\u00a0Lower legs at presentation.<\/p>\n<\/div>\n<\/div>\n

In the planning process our national protocol7<\/a><\/sup>\u00a0was followed. Briefly, while on the computer tomography (CT) simulation scanner, he was immobilised in vacuum bag (SecureVacTM Cushions, NL Tek, Willetton, Western Australia) and asked about the most symptomatic areas. These extended from proximal dorsum of both feet to the knee joints bilaterally. The areas were then decreased to measure 40cms each in maximum length as this was the limit of the three-dimensional printed bolus (3DPB) (3D One, Salisbury, QLD, Australia). A longer field would have meant that each leg would need 4 pieces of 3DPB rather than 2. \u00a0The areas for treatment were marked superiorly and inferiorly by the RO with a skin marker. The lower borders were at the eminence of the medial malleoli. To help with following any lymphoedema, graduations at 5, 10 and 15 cms above the lower border were marked. See\u00a0Figure 2<\/a>. The circumferences of the legs were measured by tape measure at those levels and recorded as baseline.<\/p>\n

<\/a><\/p>\n
\n

Figure 2A<\/strong>\u00a0At planning the patient was immobilised in vacuum bag and the areas for treatment were marked superiorly and inferiorly by the RO with a skin marker, as indicated by horizontal arrows. These fields measured 40cms in length. The lower borders were the eminences of the medial malleoli. To help with following any lymphoedema, graduations at 5, 10 and 15 cms above the lower border were marked. All RO marks were wired to enable visualistion on the CT planning scan.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 2B<\/strong>\u00a0At the second planning CT the bi-valved 3DPB was applied and kept in place with TubigripTM<\/sup>. This scan was fused with the first scan and used for RO contouring.
\nFigure 2<\/strong>\u00a0At planning.<\/p>\n<\/div>\n<\/div>\n

Wires were placed over all RO marks to capture these positions on the CT scan. The latter was done at 2mm increments. Bi-valved 3DPB was then ordered and was fitted at a second simulation session. The RO then contoured the clinical target volume (CTV) and planning target volume (PTV)8<\/a><\/sup>\u00a0according to the national protocol7<\/a><\/sup>\u00a0using MIM MaestroTM<\/sup>\u00a0planning software. A contour volume called \u201cSkin Avoid\u201d was created by having a structure that extended on all the slices on which there was a PTV. This volume was made by the RO and was 1.5cm inside the PTV into the centre of the leg. The Skin Avoid structure was prescribed to receive a dose less than a mean of 25 Gy. See\u00a0Figure 3<\/a>.<\/p>\n

<\/a><\/p>\n
\n

Figure 3A<\/strong>\u00a0The RO drew the contour of the epidermis as the CTV on the planning CT, here in light green. This is usually 2-4 mm in thickness. The white triangles denote the snugly fitting vac bag. White arrows denote the joints in the 3DPB at baseline.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 3B<\/strong>\u00a0The RO also contours the PTV, in magenta, according to the national protocol7<\/a><\/sup>\u00a0using MIM MaestroTM planning software. The PTV was prescribed 45Gy in 25 fractions. A volume called \u201cskin avoid\u201d was created by having a structure, here in cyan, that extends on all the slices on which there is a PTV. It is made by being inside and 1.5cm from the PTV into the centre of the leg. The Skin Avoid structure was prescribed to receive a dose less than a mean of 25 Gy.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 3C<\/strong>\u00a0Dosimetry with dose wash minimum set at 42.5Gy showing excellent conformality and homogeneity to the PTV.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 3D<\/strong>\u00a0Dosimetry with dose wash minimum set at 25Gy showing excellent avoidance of the skin avoid structure.
\nFigure 3<\/strong>\u00a0Contouring and dosimetry.<\/p>\n<\/div>\n<\/div>\n

A prescription was generated for PTV coverage of 45 Gy and Skin Avoid mean less than 25Gy over 25 fractions with a two week break as per protocol. Planning was done using Eclipse Version 16.1 (Varian, Palo Alto, USA). Planning constraints where met (See\u00a0table 1<\/a>). Avoidance structures were created to avoid treating the contralateral leg. Quality assurance was passed successfully. The case was presented to a peer review committee and the course of treatment was not thought unreasonable given the patients history and circumstances.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n
Volume<\/strong><\/td>\nVolume<\/strong>
\n(cm3)<\/strong><\/td>\n		Min<\/strong>
\n(Gy)<\/strong><\/td>\n		Max<\/strong>
\n(Gy)<\/strong><\/td>\n		Mean<\/strong>
\n(Gy)<\/strong><\/td>\n		Homogeneity<\/strong>
\nIndex<\/strong><\/td>\n		Conformity<\/strong>
\nIndex<\/strong><\/td>\n<\/tr>\n
Right CTV<\/td>\n319<\/td>\n39.3<\/td>\n48.9<\/td>\n45.1<\/td>\n1.088<\/td>\n1.0<\/td>\n<\/tr>\n
Right PTV<\/td>\n1071<\/td>\n39.5<\/td>\n48.9<\/td>\n44.6<\/td>\n1.088<\/td>\n0.956<\/td>\n<\/tr>\n
Right SA<\/td>\n1001<\/td>\n8.6<\/td>\n36.5<\/td>\n21.5<\/td>\nNA<\/td>\nNA<\/td>\n<\/tr>\n
 <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n
Left CTV<\/td>\n298<\/td>\n33.3<\/td>\n48.6<\/td>\n44.9<\/td>\n1.081<\/td>\n0.996<\/td>\n<\/tr>\n
Left PTV<\/td>\n1030<\/td>\n25.3<\/td>\n49.0<\/td>\n44.3<\/td>\n1.090<\/td>\n0.946<\/td>\n<\/tr>\n
Left SA<\/td>\n897<\/td>\n9.4<\/td>\n37.8<\/td>\n21.0<\/td>\nNA<\/td>\nNA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Table 1\u00a0<\/strong>Planning volumes sizes and doses
\nCTV; clinical target volume, PTV; planning target volume, SA; skin avoid volume, Max; maximum, min; Minimum, Gy; Gray, cm3; cubic centimetre<\/p>\n<\/div>\n<\/div>\n

He was treated on a HalcyonTM<\/sup>\u00a0Linear Accelerator version 3.0 (Varian, Palo Alto, USA). Both legs were treated with 2 isocentres, and 4 arcs per isocentre, a total of 16 arcs per fraction. Time in the treatment room was 20-25 minutes and beam-on time approximately 10 minutes each fraction. Regular weekly on-treatment reviews were set up, one with nurses and another with the prescribing RO. Weekly weighing was done to ensure adequate nutrition. Tape measurements of each leg was planned to take place every week and when necessary to document any change of circumference and therefore any change in diameter using the formula circumference \/ \u03c0 (Pi) =Diameter; Pi value used for calculation was 3.14. Extra repeat CT scans in the planning and treatment position were to be done when necessary to document change in volumes at the 5, 10 and 15 cm marks.<\/p>\n

Homogeneity calculation is the maximum point dose in the target divided by the reference isodose. Conformity index calculation is the volume of the structure receiving 95% dose coverage divided by the volume of the structure.<\/p>\n

The first ten fractions were delivered. Photos were taken of the legs on the day of the 10th<\/sup>\u00a0fraction showing little change (See\u00a0figure 4<\/a>). He had been applying moisturiser to his legs as instructed and was walking and swimming as usual during all this treatment time. The planned two-week break was started after fraction 10.<\/p>\n

<\/a><\/p>\n
\n

Figure 4A<\/strong>\u00a0Right leg – photos taken on the day of completing 18Gy in 10 fractions showing little change except for some mild patchy erythema as denoted by the arrows. Note that there is no alopecia yet.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 4B<\/strong>\u00a0Left leg – photos taken on the day of completion of 18Gy in 10 fractions showing similar changes.
\nFigure 4<\/strong>\u00a0Photos taken on the day of completion of 18Gy in 10 fractions.<\/p>\n<\/div>\n<\/div>\n

Ten days later he noticed some folliculitis but with no symptoms, with no pain and no systemic signs of infection. Examination showed mild erythema and some yellow exudate which could have been folliculitis infection or tumour necrosis.9<\/a><\/sup>\u00a0He was started on prophylactic flucloxacillin 500mg three times a day with good effect on symptoms. Photos were taken (See\u00a0figure 5<\/a>).<\/p>\n

<\/a><\/p>\n
\n

Figure 5A<\/strong>\u00a0A \u2013 Left leg – distant view with horizontal arrows showing areas of folliculitis \/tumour necrosis and vertical arrow showing erythema and alopecia.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 5B<\/strong>\u00a0B \u2013 Left leg – close up view with horizontal arrows showing areas of folliculitis \/tumour necrosis and vertical arrow showing erythema and alopecia.
\nFigure 5<\/strong>\u00a010 days following completing 18Gy in 10 fractions.<\/p>\n<\/div>\n<\/div>\n

He represented for a planned restart at 16 days post the 10th<\/sup>\u00a0fraction and had no pain. The legs were clinically swollen, and this was confirmed on tape measurement \u2013 see\u00a0table 2<\/a>. The RT staff noted that the bolus was not fitting as it should and surmised that this could be an early sign of lymphoedema. He had another fraction, and Cone Beam CT (CBCT) showed an increased gap in the joints of the 3DPB. A repeat CT scan was done, and on fusing the original contours, the CTV was not covering some of the anterior epidermis, a geographic miss. The posterior surface was satisfactory because presumably the gravity of the leg weight was keeping the posterior part of the CTV and PTV contours within the limb at their original position. (See\u00a0figure 6<\/a>). The volume changes were recorded \u2013 see\u00a0table 2<\/a>.<\/p>\n

<\/a><\/p>\n
\n

Figure 6<\/strong>\u00a0Rescan of Right leg at 2 weeks following completion of 18Gy in 10 fractions at 15cm proximal to medial malleolus. Compare with Figure 3A. Note swelling demonstrated by increased bolus joint width as shown by white arrows. Red arrow shows that the CTV is not covering the epidermis anteriorly, therefore causing a geographic miss. The PTV is covering more depth into the leg, especially the vascular dermis and subcutis which may set up a positive feedback loop, worsening the tendency to acute lymphoedema. The blue arrows show that posteriorly the CTV still covers the epidermis, presumably because of the weight of leg with gravity as he was treated in the supine position.<\/p>\n<\/div>\n<\/div>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n
Side<\/strong><\/td>\nDistance<\/strong>
\nfrom<\/strong>
\nMedial<\/strong>
\nmalleolus<\/strong>
\n(cm)<\/strong><\/td>\n		Baseline<\/strong>
\n\u00a0(cm)<\/strong><\/td>\n		16 days<\/strong>
\nafter<\/strong>
\n18Gy<\/strong>
\n(cm)<\/strong><\/td>\n		13 days<\/strong>
\nafter<\/strong>
\n19.8Gy<\/strong>
\n(cm)<\/strong><\/td>\n		At 39.6Gy<\/strong>
\nin 22#s<\/strong>
\n(cm)<\/strong><\/td>\n		40 days<\/strong>
\nafter<\/strong>
\n43.2 Gy<\/strong>
\n(cm)<\/strong><\/td>\n<\/tr>\n
Right<\/td>\n5<\/td>\n22<\/td>\n22.5<\/td>\n22<\/td>\n23<\/td>\n22.6<\/td>\n<\/tr>\n
 <\/td>\n10<\/td>\n23<\/td>\n25<\/td>\n24<\/td>\n25<\/td>\n24.1<\/td>\n<\/tr>\n
 <\/td>\n15<\/td>\n27.5<\/td>\n30<\/td>\n28.5<\/td>\n30<\/td>\n29.0<\/td>\n<\/tr>\n
 <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n
Left<\/td>\n5<\/td>\n22<\/td>\n22.5<\/td>\n22.5<\/td>\n23.2<\/td>\n22.6<\/td>\n<\/tr>\n
 <\/td>\n10<\/td>\n23<\/td>\n25<\/td>\n24<\/td>\n25.8<\/td>\n24.3<\/td>\n<\/tr>\n
 <\/td>\n15<\/td>\n27.5<\/td>\n30<\/td>\n28.7<\/td>\n30.2<\/td>\n29.6<\/td>\n<\/tr>\n
Pain<\/td>\n <\/td>\nNil 0<\/td>\nNil 0<\/td>\nNil 0<\/td>\nStrong 3<\/td>\nNil 0<\/td>\n<\/tr>\n
Swelling<\/td>\n <\/td>\nNil 0<\/td>\nMinimal 1<\/td>\nModerate 2<\/td>\nSignificant 3<\/td>\nMinimal 1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Table 2\u00a0<\/strong>Lower leg tape measurements over time compared with baseline and symptoms of pain and swelling. Pain and swelling ranked out of 3
\nCm; centimetre, Gy; Gray, #; fractions<\/p>\n<\/div>\n<\/div>\n

Another break of two weeks was advised, with a planned second rescan prior to restarting. Five days into this two-week break, he developed left groin lymphadenopathy but no had systemic signs of infection. He was started on antibiotics with resolution of the groin node. Whether this was due to infection or just continuing resolution of the swelling from the RT is unknown. He presented for continued treatment as planned two weeks later, 13 days after 19.8Gy, four weeks after fraction 10. Tape measurement and a CT rescan was done and values recorded. See\u00a0tables 2<\/a>\u00a0and 4. Treatment recommenced with aim of completing the whole prescription.\u00a0Figure 7<\/a>\u00a0shows the anti – lymphoedema garments (EasywrapTM<\/sup>\u00a0by Haddenham Healthcare, Mount Waverley, Victoria, Australia) used.\u00a0Tables 3<\/a>\u00a0and 5 show the change from base line overtime in tape measurement and CT volumes at 15 cm respectively.<\/p>\n

\n\n\n\n\n\n\n
Side<\/strong><\/td>\nBase<\/strong>
\nline<\/strong>
\nCir\/<\/strong>
\nDia<\/strong><\/td>\n		At\u00a0<\/strong>16 dys<\/strong>
\nafter<\/strong>
\n18Gy<\/strong>
\nCir<\/strong>
\n\/Dia<\/strong><\/td>\n		Diff<\/strong>
\nto Base<\/strong><\/td>\n		At 13 dys<\/strong>
\nafter<\/strong>
\n19.8Gy<\/strong>
\nCir<\/strong>
\n\/Dia<\/strong><\/td>\n		Diff<\/strong>
\nto Base<\/strong><\/td>\n		At 39.6Gy<\/strong>
\nin 22#s<\/strong><\/td>\n		Diff<\/strong>
\nto Base<\/strong><\/td>\n		40 dys<\/strong>
\nafter<\/strong>
\n43.2 Gy<\/strong><\/td>\n		Diff<\/strong>
\nto Base<\/strong><\/td>\n<\/tr>\n
R<\/td>\n27.5\/
\n8.76<\/td>\n		30\/
\n9.55<\/td>\n		+0.79<\/td>\n28.5\/
\n9.08<\/td>\n		0.47<\/td>\n30.0\/
\n9.55<\/td>\n		0.79<\/td>\n29\/
\n9.23<\/td>\n		0.48<\/td>\n<\/tr>\n
L<\/td>\n27.5\/
\n8.76<\/td>\n		30\/
\n9.55<\/td>\n		+0.79<\/td>\n28.7\/
\n9.1<\/td>\n		0.45<\/td>\n30.2
\n9.6<\/td>\n		0.79<\/td>\n29.6\/
\n9.4<\/td>\n		0.64<\/td>\n<\/tr>\n
Ave<\/td>\n0<\/td>\n <\/td>\n0.79<\/td>\n <\/td>\n0.46<\/td>\n <\/td>\n0.79<\/td>\n <\/td>\n0.56<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Table 3\u00a0<\/strong>Change in diameter at 15cm by tape measure\u2013 all measurements in cm
\nUsing formula Circumference\/ \u03c0 (Pi) = Diameter; Pi value used is 3.14
\nAve; Average, Cir; Circumference, Cm; centimetre, Dia; Diameter, Diff; difference, Dys; days, Gy; Gray, L; Left, R; Right<\/p>\n<\/div>\n<\/div>\n

\n\n\n\n\n\n\n\n\n\n\n
Leg<\/strong>\u00a0<\/strong><\/td>\nCm above medial malleolus<\/strong>\u00a0<\/strong><\/td>\nBaseline<\/strong>
\n(cm3)\u00a0<\/strong><\/td>\n		Rescan<\/strong>
\n16 days after 18Gy<\/strong>
\n\u00a0(cm3)<\/strong><\/td>\n		Rescan<\/strong>\u00a0<\/strong>
\n13 days after<\/strong>
\n19.8Gy<\/strong>
\n\u00a0(cm3)<\/strong><\/td>\n		Rescan<\/strong>\u00a0<\/strong>
\nAt 39.6 Gy in 22#s<\/strong>
\n(cm3)<\/strong><\/td>\n		Rescan<\/strong>
\n40 days after<\/strong>
\n43.2 Gy<\/strong>
\n(cm3)<\/strong><\/td>\n<\/tr>\n
Right<\/td>\n5<\/td>\n204.4<\/td>\n217.2<\/td>\n217.6<\/td>\n229.1<\/td>\n\u00a0225.3<\/td>\n<\/tr>\n
 <\/td>\n10<\/td>\n407.0<\/td>\n436.2<\/td>\n438.2<\/td>\n460.1<\/td>\n\u00a0442.3<\/td>\n<\/tr>\n
 <\/td>\n15<\/td>\n685.5<\/td>\n738.7<\/td>\n735.8<\/td>\n771.0<\/td>\n\u00a0727.3<\/td>\n<\/tr>\n
 <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n
Left<\/td>\n5<\/td>\n216.2<\/td>\n222.2<\/td>\n229.7<\/td>\n244.8<\/td>\n\u00a0236.6<\/td>\n<\/tr>\n
 <\/td>\n10<\/td>\n421.4<\/td>\n447.1<\/td>\n452.3<\/td>\n479.1<\/td>\n\u00a0455.7<\/td>\n<\/tr>\n
 <\/td>\n15<\/td>\n701<\/td>\n754.1<\/td>\n751.5<\/td>\n783.1<\/td>\n\u00a0743.6<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Table 4\u00a0<\/strong>Lower leg CT volume measurements over time
\nCm; centimetre, cm3<\/sup>; cubic centimetre, Gy; Gray, #; fractions<\/p>\n<\/div>\n<\/div>\n

\n\n\n\n\n\n\n
Side<\/strong><\/td>\nBase<\/strong>
\nline<\/strong><\/td>\n		At\u00a0<\/strong>16 dys<\/strong>
\nafter<\/strong>
\n18Gy<\/strong><\/td>\n		Diff<\/strong>
\nto Base<\/strong><\/td>\n		At 13 dys<\/strong>
\nafter<\/strong>
\n19.8Gy<\/strong><\/td>\n		Diff<\/strong>
\nto Base<\/strong>
\n\u00a0<\/strong><\/td>\n		At 39.6Gy<\/strong>
\nin 22#s<\/strong><\/td>\n		Diff<\/strong>
\nto Base<\/strong><\/p>\n

\u00a0<\/strong><\/td>\n

40 dys<\/strong>
\nafter<\/strong>
\n43.2 Gy<\/strong><\/td>\n		Diff<\/strong>
\nto Base<\/strong><\/td>\n<\/tr>\n
R<\/td>\n685.5<\/td>\n738.7<\/td>\n+53.2<\/td>\n735.8<\/td>\n50.3<\/td>\n771.0<\/td>\n85.5<\/td>\n\u00a0727.3<\/td>\n41.8<\/td>\n<\/tr>\n
L<\/td>\n701<\/td>\n754.1<\/td>\n+53.1<\/td>\n751.5<\/td>\n50.5<\/td>\n783.1<\/td>\n82.1<\/td>\n743.6<\/td>\n42.6<\/td>\n<\/tr>\n
Ave<\/td>\n0<\/td>\n <\/td>\n53.2<\/td>\n <\/td>\n50.4<\/td>\n <\/td>\n83.8<\/td>\n <\/td>\n42.2<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Table 5\u00a0<\/strong>Change in CT volume at 15cm compared with baseline \u2013 all in cm3<\/sup>
\nUsing formula Circumference\/ \u03c0 (Pi) =Diameter; Pi value used is 3.14
\nAve; Average, Gy; Gray, #; fraction, Cir; Circumference, Cm; centimetre, Dia; Diameter, Diff; difference, L; Left, R; Right<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 7A<\/strong>\u00a0Under Sock.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 7B<\/strong>\u00a0External face of lower leg wrap garment to check lymphoedema .<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 7C<\/strong>\u00a0Internal face of lower leg wrap garment to check lymphoedema.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 7D<\/strong>\u00a0Foot garment anterior view.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 7E<\/strong>\u00a0Foot garment applied – anterior view.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 7F<\/strong>\u00a0Leg and foot garment applied \u2013 lateral view.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 7G<\/strong>\u00a0Leg and foot garment applied \u2013 anterior view.
\nFigure 7<\/strong>\u00a0Personalised flat knit compression wrap-style garments used (EasywrapT<\/sup>M by Haddenham Healthcare, Mount Waverley, Victoria, Australia).<\/p>\n<\/div>\n<\/div>\n

At on treatment review after 39.6 Gy in 22 fractions, the legs were again clinically swollen with erythema and now with pain despite regular paracetamol. See\u00a0Figure 8<\/a>. He complained that the pain was like \u201clava\u201d just inside the skin of the leg, worse at the ankle posteriorly. It reminded him of the PDT. \u00a0He was waking up with burning sensations in his legs and had resorted to elevation with towels soaked in cold salty water on his legs during the day. Regular thickly applied moisturiser and FlamigelTM<\/sup>\u00a0gave symptom relief. Tape measurements were taken and a rescan organised and recorded. See\u00a0tables 2<\/a>\u00a0and 4. The last fraction, the 25th<\/sup>\u00a0was cancelled. The total dose given was 43.2Gy in 24 fractions.<\/p>\n

<\/a><\/p>\n
\n

Figure 8A<\/strong>\u00a0Legs after 22 fractions of RT- Anterior View.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 8B<\/strong>\u00a0Legs after 22 fractions of RT- Anterior View. Close up.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 8C<\/strong>\u00a0Legs after 22 fractions of RT- Posterior View.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 8D<\/strong>\u00a0Legs after 22 fractions of RT- Posterior View. Close up.
\nFigure 8<\/strong>\u00a0Legs after 39.6 Gy in 22 fractions of RT.<\/p>\n<\/div>\n<\/div>\n

Day 6 following completion of treatment he was essentially housebound due to pain. The skin had become \u201cflaky\u201d. When he rose from a reclining position, he felt the \u201clava\u201d type pain in his legs worse at the back of knee and ankle on the Achilles tendon, where the skin stretches more on walking. On standing the legs were sore and his feet would throb. The skin was bright red and ankles were swollen. See\u00a0Figure 9<\/a>.<\/p>\n

<\/a><\/p>\n
\n

Figure 9<\/strong>\u00a0Legs at Day 6 post all RT. The skin had become flaky and was bright red and ankles were swollen.<\/p>\n<\/div>\n<\/div>\n

To reduce symptoms, he lay down and elevated legs above heart level and wrapped his legs in cool saline-soaked towels over both legs. Swelling was controlled with the compression garments. He preferred to keep moving rather than standing and was walking more up to 2 kilometres a day around his apartment. A prophylactic massage prior to rising from lying to standing with moisturiser and FlamigelTM<\/sup>\u00a0decreased the intensity of pain on rising. He remained on regular Panadol and needed oxycodone 10 mg nocte to sleep at night. The \u201cfolliculitis\u201d had returned and flucloxacillin 500mg three times a day was restarted with good effect on symptoms of yellow heads within the treatment volumes.<\/p>\n

Day 10 following cessation of RT he noticed that the pain was getting less and he could stand for up to an hour. On day 14 he was off pain relief, there was no more \u201dlava\u201d pain. From days 10-14 there was significant shedding of dead skin.<\/p>\n

Forty days after the last fraction of RT tape measurements were taken and a rescan organised and recorded. See\u00a0tables 2<\/a>\u00a0and 4. The pain and swelling clinically had subsided. See\u00a0Figure 10<\/a>. The small, dry, scaly brown patches of DSAP had disappeared. At seventy days, there was continuing response in terms of DSAP and no pain; he said after a round of golf he said there was mild swelling which dissipated within a short time.<\/p>\n

<\/a><\/p>\n
\n

Figure 10A<\/strong>\u00a0Legs at 40 days post RT – Anterior View.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 10B<\/strong>\u00a0Legs at 40 days post RT – Anterior View. Close up.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 10C<\/strong>\u00a0Legs at 40 days post RT – Posterior View.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Figure 10D<\/strong>\u00a0Legs at 40 days post RT – Posterior View. Close up.
\nFigure 10<\/strong>\u00a0Legs at Day 40 post RT showing resolution of DSAP.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Chart 1<\/strong>\u00a0Time course of treatment. Chart shows fractions delivered over days. Baseline is at day 1. Rescan 16 days after 18Gy is at day 28. Rescan .
\n13 days after 19.8Gy is at day 42. Rescan at 39.6 Gy in 22 fractions is at day 57.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/p>\n
\n

Chart 2<\/strong>\u00a0Comparison of reported changes in percentage of pain, swelling on examination, tape measure and CT Volumes compared to baseline over time. The initial pain score and swelling was zero at baseline.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

Discussion<\/h1>\n
\n

We present a case of a fit 65-year-old male with a long history of recalcitrant DSAP treated with VMAT to the whole circumference of both lower legs simultaneously, with in-field clearance of disease at four weeks with continuing complete response at 10 weeks. This is the first publication of circumferential VMAT lower leg treatment, and of both legs simultaneously.<\/p>\n

There is no standard treatment for DSAP, and treatment is generally not effective long-term.1<\/a>,2<\/a><\/sup>\u00a0Symptom relieving treatments include topical imiquimod cream, topical 5-fluorouracil, and topical vitamin D analogs such as tacalcitol and calcipotriol and topical cholesterol\/lovastatin10<\/a><\/sup>. Cryotherapy, electrodessication (using electrical currents to remove patches), laser ablation, and photodynamic therapy have also been tried.1<\/a>,2<\/a>,3<\/a><\/sup><\/p>\n

There are limitations and exceptions in this case:<\/p>\n

    \n
  1. The lower legs were treated circumferentially which is not in accord with our protocol which recommends a \u201cspare strip\u201d.<\/li>\n
  2. The lower legs were treated simultaneously which is not according to our national protocol.<\/li>\n
  3. The PTVs were larger than the size when breaking up the PTV into smaller for sequential treatment is advised12<\/a><\/sup>.<\/li>\n
  4. He did have pain.<\/li>\n
  5. The full prescription treatment was not delivered.<\/li>\n<\/ol>\n

    However, the case shows that VMAT lower leg circumferential treatment is possible in select patients.<\/p>\n

    The technique of VMAT to the lower legs for ESFC continues to evolve. With this technique, there have been cases of pain, described as a burning sensation, like \u201clava\u201d when the leg is moved from an elevated position to a dependent one, beginning at about 25-30 Gy. This pain is not responsive to opiates and is worse in those with a history of vascular problems especially varicosities (Brad Wong personal communication). Patients have not completed treatment due to this symptom. Incomplete treatment runs the risk of treatment failure with increased risk of infield recurrence at 12 months.5<\/a><\/sup>\u00a0This symptom has led to a mandated break in our national protocol7<\/a><\/sup>\u00a0of at least two weeks after 18-20 Gy in lower legs, and to treating one leg at a time. Other problems due to decreased dose, like keratoacanthoma,11<\/a><\/sup>\u00a0can also occur when treatment is not completed.<\/p>\n

    There have been learnings from this case:<\/p>\n

      \n
    1. Circumferential treatment is possible in select patients.<\/li>\n
    2. Acute effects are seen two weeks into a break started after the first ten fractions of RT have been delivered. Prolonging the break until resolution is an option rather than ceasing treatment. Difficulties in completing the prescription were expected as the PTVs were both over the 800cm3<\/a><\/sup>\u00a0limit suggested by Wong et\u00a012<\/a><\/sup><\/li>\n
    3. Tape measurement at 15cm superior from the medial malleolus showed the most change compared with more inferior levels. This may be different in a different patients.<\/li>\n
    4. A small change in the circumference meant a significant change in the diameter of the leg and therefore a geographic miss of the epidermis, especially anteriorly when treated supine. This may lead to more dose being delivered to the dermis and subcutis, so setting up a positive feedback loop which leads to more acute lymphoedema. It is very important to control this so that treatment is finished with as less pain as possible and in a timely manner.<\/li>\n
    5. The need for having a \u201cspare skin strip\u201d\u00a09<\/a><\/sup>\u00a0as was done in the days of less complex RT modalities in sarcoma treatment,13<\/a><\/sup>\u00a0has also been recommended in our national protoc7<\/a><\/sup>\u00a0This case shows that the strip may not be necessary in select patients.<\/li>\n
    6. The chart showing comparison of reported pain, swelling in examination, tape measure change and CT Volume changes compared to baseline shows that, in this solitary case that the pain came on suddenly but well after changes on with the tape measure were present. CT volume changes were not as reliable as tape measurement changes. It seems regular measurement of circumference with a tape measure 15 cms above the medial malleolus is a possible way of knowing when to increase the break to avoid pain and the possibility of treatment being curtailed. More study is needed.<\/li>\n
    7. Another learning is that VMAT may be a treatment option for DSAP. Longer follow-up is necessary to see if this treatment is durable.<\/li>\n<\/ol>\n

      This case suggests a way forward for refining our lower leg VMAT ESFC technique, especially when the PTV is large:<\/p>\n

        \n
      1. Routine referral to a lymphoedema physiotherapist at planning for personalised compression garments to wear from treatment start should be done, with regular review to ensure compliance.<\/li>\n
      2. At planning, measure the circumference at 15cm above the medial malleolus and follow during treatment. A change in the circumference of 10 mm from baseline may mean impending lymphoedema and a break should be started before symptoms develop.<\/li>\n
      3. Involve the nurses especially for weekly weighing to ensure adequate nutrition.<\/li>\n
      4. Treat to 18 Gy in 10 fractions at 5 fractions per week. Then a break of at least 3 weeks. Measure again. Break until the leg measurement starts to reverse back towards to the baseline circumference.<\/li>\n
      5. Be aware that if the bolus is not fitting as it should, this could be an early sign of lymphoedema developing.<\/li>\n
      6. Treat to prescription dose, using more breaks if necessary.<\/li>\n<\/ol>\n

        To reduce the chance of lymphoedema even more, active lesions requiring more dose may benefit from a review at 6 weeks following RT completion. A phase 2 electron boost to 60Gy total equivalent can then be added and may be better than a simultaneous integrated boost (SIB) in terms of lymphoedema risk. This is because the active lesion may shrink with the first course of RT, meaning the phase 2 PTV of the active lesion is smaller than that at the beginning. This is found in the adaptive split course.14<\/a>,15<\/a><\/sup>\u00a0This means less normal tissue is involved than in using an SIB, perhaps reducing the chance of lymphoedema. It also means less dose differential which may also play a role in reducing lymphoedema.<\/p>\n<\/div>\n

        Conclusion<\/h1>\n
        \n

        We present a case of a fit 65-year-old male with a long history of recalcitrant DSAP treating the whole circumference of both lower legs simultaneously using VMAT with in-field clearance of disease at ten weeks. This is the first publication of circumferential VMAT lower leg treatment, and circumferential treatment of both legs with VMAT simultaneously. Despite the limitations and exceptions in this case, there were considerable learnings, and this resulted in suggesting a way forward in treating the lower legs circumferentially in select patients, especially in symptomatic recalcitrant diseases like DSAP that involve the whole lower leg circumference.<\/p>\n<\/div>\n

        Acknowledgments<\/h1>\n
        \n

        The authors would like to acknowledge the patient for allowing his case to be published; Lori Lewis of Senior Research Officer at Australian Lymphoedema Education, Research and Treatment Unit, Macquarie University, Sydney; and the staff of GenesisCare Radiation Oncology, Mater Hospital, Sydney, Australia.<\/p>\n<\/div>\n

        Conflicts of interest<\/h1>\n
        \n

        None.<\/p>\n<\/div>\n

        References<\/h1>\n
        \n
          \n
        1. Disseminated superficial actinic porokeratosis. DermNet NZ<\/em>. 2021.<\/a><\/u><\/li>\n
        2. Kanitakis J. Disseminated superficial actinic porokeratosis.\u00a0Orphanet<\/em>. 2015.<\/a><\/u><\/li>\n
        3. Touitou I. et al. The expanding spectrum of rare monogenic autoinflammatory diseases.\u00a0Orphanet Journal of Rare Diseases<\/em>. 2013;8:162.<\/a><\/u><\/li>\n
        4. Fogarty GB, Christie D, Spelman LJ, et al. Can modern radiotherapy be used for extensive skin field cancerisation: an update on current treatment options.\u00a0Biomed J Sci & Tech Res<\/em>. 2018;4(1).<\/a><\/u><\/li>\n
        5. Fogarty GB, Young S, Lo S, et al. Field-based radiotherapy using volumetric modulated arc therapy (VMAT) for skin field cancerisation (SFC) \u2013 outcomes from 100 consecutive fields. Int J Radiol<\/em>\u00a0Radiat Ther<\/em>. 2021;8(1):13\u201224.<\/a><\/u><\/li>\n
        6. Tighe DG, Tanous A, Flood J, et al. Lesion-based radiotherapy for non-melanoma skin cancer of the lower legs with a focus on radiation-induced ulcers.\u00a0Int J Radiol Radiat Ther<\/em>. 2021;8(2):44\u201254.<\/a><\/u><\/li>\n
        7. Potter A, Price M, Papworth D, et al. A technique for treating extended skin field cancerisation using volumetric modulated arc therapy.\u00a0Int J Radiol Radiat Ther<\/em>. 2019;6(4):111\u2012119<\/a><\/u><\/li>\n
        8. ICRU 50 – NG Burnet, SJ Thomas, KE Burton, et al. Defining the tumour and target volumes for radiotherapy.\u00a0Cancer Imaging<\/em>. (2004);4(2):153\u2013161.<\/a><\/u><\/li>\n
        9. Fogarty GB, Christie D, Potter A. Volumetric modulated arc therapy (VMAT) for extended skin field cancerisation (ESFC): Radiobiological learnings from unique patient cases.\u00a0Int J Radiol Radiat Ther.<\/em>\u00a02019;6(5):156\u2012162.<\/a><\/u><\/li>\n
        10. Atzmony L, Lim YH, Hamilton C, et al. Topical cholesterol\/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy.\u00a0J Am Acad Dermatol<\/em>. 2020;82(1):123\u2012131.<\/a><\/u><\/li>\n
        11. Mullin SJ, Lochhead A, Haddad R, et al. Keratoacanthomas following definitive volumetric modulated arc radiotherapy for skin field cancerization.\u00a0Int JRadiol Radiat Ther<\/em>. 2019;6(6):225\u2012232.<\/a><\/u><\/li>\n
        12. Wong B, Christie D, Hellyer J, et al. Volumetric modulated arc therapy (VMAT) for extensive skin field cancerisation (ESFC) \u2013 exploring the limits oftreatment volumes with a case series of backs.\u00a0Int J<\/em>\u00a0Radiol Radiat Ther<\/em>. 2020;7(6):184\u2012192.<\/a><\/u><\/li>\n
        13. Tepper J, Rosenberg SA, Glatstein E. Radiation therapy technique in soft tissue sarcomas of the extremity–policies of treatment at the National Cancer Institute.\u00a0Int J Radiat Oncol Biol Phys.<\/em>\u00a01982;8(2):263\u2012273.<\/a><\/u><\/li>\n
        14. Fogarty GB, McLaren KR, Moutrie Z, et al. Locally advanced skin cancers of the frail and elderly – consider adaptive split course radiotherapy (ASCRT).\u00a0Br J Dermatol<\/em>. 2018;179(6):1416\u20121417.<\/a><\/li>\n
        15. Carney GR, McLaren KR, Moutrie Z, et al. Adaptive Split Course Radiotherapy for Skin Cancers Decreases Toxicity and Improves Compliance.\u00a0Int J Radiol Radiat Ther<\/em>. 2017;2(1):00015.<\/a><\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

          Gerald B. Fogarty,1\u00a0\u00a0Chris Farrow,1\u00a0Julie Bartley,1\u00a0Steven Wardle,2\u00a0Reza Rahbari,3\u00a0Chelsie O\u2019 Connor1 1GenesisCare Radiation Oncology, Mater Hospital, Crows Nest, Australia 2Sun Doctors, 200 Crown Street, Wollongong, Australia 3GenesisCare Centre for Radiation Oncology, Waratah … <\/p>\n","protected":false},"author":1,"featured_media":968,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-967","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/posts\/967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=967"}],"version-history":[{"count":1,"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/posts\/967\/revisions"}],"predecessor-version":[{"id":969,"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/posts\/967\/revisions\/969"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/media\/968"}],"wp:attachment":[{"href":"https:\/\/edmpackz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}